Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4194)	1/7/2003 8:54:13 AM
From: Mike M	Read Replies (2) \| Respond to of 5582

Some revenue news: biz.yahoo.com Matrixx Initiatives, Inc. Increases 2002 Top-Line Revenue Guidance Tuesday January 7, 7:31 am ET Zicam(R) Cold Remedy Manufacturer Projects Profitability and More Than 40% Year-Over-Year Growth PHOENIX, Jan. 7 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX - News), developer and distributor of the expanded line of Zicam® products, today announced that its year-over-year revenue growth will surpass previous guidance of 25-30 percent, based on initial, unaudited fourth quarter results. The upgraded projected growth in sales during 2002 is expected to exceed 40 percent over 2001 sales and reflects a doubling of fourth quarter sales above the comparable period in 2001. ADVERTISEMENT The guidance upgrade followed last week's announcement of new research reinforcing the efficacy of zinc gluconate -- the active ingredient in the proprietary Zicam Cold Remedy nasal gel formula -- to reduce the duration and severity of the common cold. "More and more consumers are discovering the value of Zicam as a compelling alternative to conventional cough and cold products that simply mask the symptoms," said Carl J. Johnson, president and chief executive officer. "The consumer response, coupled with high profit potential, has strengthened our retail partnerships and increased interest in the five new products we launched last September." Matrixx also indicated that it expects to report a slight profit from operations in the fourth quarter of 2002 and reiterated previous guidance that it would be profitable and cash flow positive for the full year. For the nine months ended September 30, 2002, the Company reported net income of $1.08 million, or $0.11 per share. In 2001, the Company reported net sales of $16.1 million and a net loss from continued operations of $0.53 per share. "This has been an incredible year for Matrixx," said Mr. Johnson. "At a time when many companies are experiencing a downturn in sales and profits, we have consistently outperformed against both the market and our initial projections. Through the outstanding commitment of everyone in our organization, and the support of our Board and customers, it appears, based on our preliminary review, that we have met and exceeded our 2002 goals and believe we have established an excellent foundation for continued growth in 2003." The company expects to report its fourth quarter and final 2002 financial results in mid-February.

To: DanZ who wrote (4194)	1/7/2003 9:01:12 AM
From: Mike M	Read Replies (1) \| Respond to of 5582

Sorry to have to post this but you can't seem to find a Truthseeker when you need one. <g> Reuters: biz.yahoo.com Reuters Matrixx Initiatives boosts 2002 revenue view Tuesday January 7, 8:15 am ET PHOENIX, Jan 7 (Reuters) - Matrixx Initiatives (NasdaqNM:MTXX - News), a maker of nasally-delivered, over-the-counter cold medication, said on Tuesday that it expects to beat its prior revenue forecast for 2002, due to strong demand after the release of new research highlighted the effectiveness of an ingredient it uses in its products. Matrixx, whose products are marketed under the Zicam name, said its 2002 sales are expected to increase by more than 40 percent over 2001, driven by a doubling of fourth-quarter sales over the prior-year period. Research indicating that an ingredient used in some of its products -- zinc gluconate -- helped reduce cold symptoms, had increased interest in its products from retailers, Matrixx said. Matrixx also said it expects to post a small profit from operations in the fourth quarter. It also said it was on track to be profitable and cash flow positive for the full year.

To: DanZ who wrote (4194)	1/7/2003 2:27:51 PM
From: Hank	Read Replies (1) \| Respond to of 5582

"Assuming a treatment effect size of 30% and significance level of a = 0.05, the power to detect a significant difference between both groups with 80 total subjects was 70%." Bullshit. You only have an effective sample population of 18 people because that is the number that were confirmed to have a rhinoviral infection- not 80. The data on the rest of the subjects is invalid because you can not positively define the cause of the symptoms you are measuring. Hence, you can not account for possible differences in symptom duration that may be inherent in different causative agents. Now throw in the fact that there over 200 types of rhinoviruses and things become even less clear. The maximum number of rhinoviral serotypes that could have been tested based on the confirmed number of rhinoviral infections is 18, or a maximum theoretical 9% of the total number of rhinoviruses known to cause cold symptoms. Of course, it's highly unlikely that we're talking about the maximum here since it's extremely unlikely that each of 18 subjects had different viruses. But hey look on the bright side. Their TV ads are better than they were.